Checklist for Actemra (tocilizumab) Referral

Required documentation for all initial referrals

Patient		DOB	Date	🗆 New Start 🗆 Maintenance			
Please	return completed checklist and	l checklist items for an inf	usion referral:				
	Patient demographics (e.g. address, phone number, SSN, etc.)						
	 Insurance information and copy of insurance card(s). Please indicate the insurance that is primary, and the insurance that is secondary, if applicable, and the subscriber's date of birth. If insurance requires prior authorization, please provide the phone number and allow up to 15-30 days for this to be completed by one of our Infusion Coordinators. 						
	Signed and completed Actemra Standard Order (our order form) with ICD diagnosis code • Standard Order forms are available at lowcountryrheumatology.com/infusions/						
	Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy, and how long patient has been on Actemra.						
	Lab results and/or tests to supp o Pre-Screening:	ort diagnosis.					
	 Required TB sci Required Hepaten Antibody, or Hematical Science Antibody and the science Antibody antibody	titis screening (within 1 ye patitis B Core Antibody res	ar): Hepatitis B Sur sults and Hepatitis (FERON Gold Test <i>(within 3 years)</i> face Antigen, Hepatitis B Surface C Antibody results e ANC, AST & ALT) and Lipid Panel			
	Please indicate name and direct any additional information: • Name:		ct within your office	e that we can speak with to obtain			
	 Phone Number: 						
F	Paperwork can be faxed or en	nailed to (843)-824-2327	, <u>infusionemail@</u>	Darticularishealthcare.com			
	Infusion Coordinators Bre	enna, Sadie or Stephan	ie will assist you	with any questions at			
		(843)-572-89	932				
	Lo	w Country Rheumatology I	nfusion Locations				
	Please mark preferred location and	we will do our best to accom	modate, however we	e cannot make any guarantees.			
	200	Summerville 1 2nd Ave, Suite 201, Sum					
		Mount Pleasa					
	116	5 Chuck Dawley Blvd, Mt. I					
	2291	West Ashley Henry Tecklenburg Drive, (•	4			
docume informa review	ation is required. The patient wil	ce company for eligibility. I have an annual 30-minut	Our Infusion Coord e consult with our I	l submit all required clinical inators will notify you if any further NP to obtain H&P for chart. We will assistance as required. Thank you			
Low	Country Rheumatology Use Only	Existing Patient Yes No	Physiciar	·			

Standard Orders for Actemra (tocilizumab) Administration

Patient	DOBD	ate				
Indication:						
MO5.79 RA w/rheumatoid factor of multiple sites w/o organ involvement	MO6.09 RA w/o rheumatoid factor, multiple sites	Other				
History: MUST have had inadequate response to DI Swollen/tender joints 	MARD	 Unable to tolerate DMARDS ESR 				
□ HBsAg, HBsAb, HB core Ab, HCAb						
Standard Order Protocol:						

- Confirm current Tspot or CXR; Confirm HbsAg negative
- Obtain patient weight each visit
- Evaluate patient for active infections, prior or upcoming appointments, medication allergies, history of liver disease, history of diverticulitis, or any other current health concerns as noted on Infusion Record
- Normal Saline Flush KVO before infusion.
- Baseline vitals will be obtained prior to administration, and at the end of the infusion (or hourly if infusion > 1 hour length until infusion is complete) and more frequently if patient's condition warrants it.
- If infusion reaction occurs, slow or stop infusion, and initiate infusion reaction protocol per Articularis Healthcare Policy and Procedure Manual.
- Discharge instructions to include possible infusion side effects and follow-up appointment schedule

Dosage: Tocilizumab (Actemra) IV infusion should be administered over 60 minutes or greater as tolerated every 4 weeks.

- □ Tocilizumab (Actemra) 4mg/kg in 100ml Normal Saline IV
- □ Tocilizumab (Actemra) 8mg/kg in 100ml Normal Saline IV

Labs: Should be verified as current (within 60 days) and within normal limits prior to each infusion.

DO NOT INITIATE THERAPY IF:	ANC < 2000 cells/ mm ³	Platelets < 100,000mm ³	ALT/AST > 1.5x UNL		
Standard Lab Dratacal					

Standard Lab Protocol:

- Do not check labs less than 2 weeks after infusion
- CBC w/diff and Platelets at weeks 4 and 8; then every 12 weeks
- CMP 14 at weeks 4 and 8; then every 12 weeks
- Lipid Panel at week 8; then every 6 months as maintenance

Neutrophils (cells/mm ³)	During treatment with Actemra
ANC > 1000	Maintain dose
ANC 500 to 1000	Interrupt Actemra dosing
	When ANC > 1000 cells/mm ³ resume Actemra at 4mg/kg and increase to 8mg/kg as
	clinically appropriate
ANC < 500	Discontinue Actemra
Platelets	During treatment with Actemra
50,000 to 100,000	Interrupt Actemra dosing
	When platelet count is > 100,000 cells/mm ³ resume Actemra at 4mg/kg and increase
	to 8mg/kg as clinically appropriate
< 50,000	Discontinue Actemra
ALT/AST	During treatment with Actemra
> 1.5 to 3x UNL	Reduce Actemra dose to 4mg/kg or interrupt dose until lab values normalize
> 3 to 5x UNL	Interrupt Actemra dosing until <3x UNL and follow recommendations for > 1.5 to 3x
	UNL
> 5x UNL	Discontinue Actemra

Additional orders/comments:

Practice Name:	
Physician Name:	State License:
Physician Signature:	DEA #:
Date:	UPIN: